Total pancreatectomy with islet cell autotransplant (TPIAT) is a definitive therapeutic approach to pain management for patients with chronic pancreatitis that is non-responsive to maximum medical management. Total pancreatectomy (TP) results in brittle diabetes unless islet cell autotransplant (IAT) is concomitantly performed. Even with IAT, about 30 % of patients will require long-term basal-bolus insulin therapy due to significant endocrine insufficiency. The focus of this review is on the utility of whole organ pancreas transplantation toward improving quality of life, and decreasing the risk of mortality and overall cost of care for the subset of patients who experience endocrine and exocrine deficiency after pancreatic resection.
Bibliographical noteFunding Information:
Ty B. Dunn, Varvara A. Kirchner, K. Louise Berry, Melena D. Bellin, David E.R. Sutherland, and Timothy L. Pruett declare that they have no conflict of interest. This article does not contain any studies with human or animal subjects performed by any of the authors.
- Brittle diabetes
- Pancreas transplant
- Quality of life
- Total pancreatectomy